The BCG vaccine: information and recommendations for use in Australia: National Tuberculosis Advisory Committee update October 2012
DOI:
https://doi.org/10.33321/cdi.2013.37.7Keywords:
tuberculosis, disease surveillance, BCG vaccineAbstract
The BCG vaccine: information and recommendations for use in Australia (March 2006) has been updated to incorporate the most recent trends in annual national tuberculosis (TB) surveillance data. Australia continues to meet international epidemiological criteria that limit bacille Calmette-Guérin (BCG) vaccination to selected high risk groups in countries with a low incidence of TB. No significant change has been made to existing recommendations for BCG vaccination in Australia.
Downloads
References
International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guérin (BCG) in countries with a low prevalence of tuberculosis. Tuber Lung Dis 1994;75:179–181
Styblo K. Epidemiology of Tuberculosis. Selected Papers, 24. Royal Netherlands Tuberculosis Association, 1991.
Romanus V, Svensson A, Hallander HO. The impact of changing BCG coverage on tuberculosis incidence in Swedish born children between 1969 and 1989. Tuber Lung Dis 1992;73,150–161.
Romanus V. Surveillance report. Selective BCG vaccination in a country with low incidence of tuberculosis. Euro Surveill 2006;11(3).
Zwerling et al. The BCG World Atlas: A Database of Global BCG vaccination Policies and Practices. PLoS Med 2011;8(3): e1001012 doi: 10.1371/journal.pmed. 1001012
Clemens JD, Chuong JJ, Feinstein AR. The BCG controversy: a methodological and statistical reappraisal. JAMA 1983;249:2362–2369.
Smith PG. Case-control studies of the efficacy of BCG against tuberculosis. In: International Union Against Tuberculosis, ed. Proceedings of the XXVIth IUAT World Conference on Tuberculosis and Respiratory Diseases. Singapore: Professional Postgraduate Services International, 1987;73–79.
Tripathy SP. Fifteen-year follow-up of the Indian BCG prevention trial. In: International Union Against Tuberculosis, ed. Proceedings of the XXVIth IUAT World Conference on Tuberculosis and Respiratory Diseases. Singapore: Professional Postgraduate Services International, 1987;69–72.
The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996;45 (RR–4):1–18.
Fine PE, Carneiro IA, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunization programmes. A discussion document. Department of Vaccines and Biologicals, World Health Organization; Geneva: 1999.
Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698–702.
Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22:1154–1158.
Stevens JP, Daniel TM. Bacille Calmette-Guérin immunization of health care workers exposed to multidrug-resistant tuberculosis: a decision analysis. Tuber Lung Dis 1996;77:315–321.
Marcus AM, Rose DN, Sacks HS, Schechter CB. BCG vaccination to prevent tuberculosis in health care workers: a decision analysis. Prev Med 1997;26:201–207.
Greenberg PD, Lax KG, Schechter CB. Tuberculosis in house staff. A decision analysis comparing the tuberculin screening strategy with the BCG vaccination. Am Rev Respir Dis 1991;143:490–495.
Stapledon RA, Lumb R, Lim IS. Chemoprophylaxis and BCG in contacts of multidrug resistant tuberculosis. Chapter 14, 213–224. In: Bastian I, Portaels F, eds. Multidrug-resistant tuberculosis. Kluwer Academic Publishers. The Netherlands 2000.
Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 1992;41 (RR–11):61–71.
Office of Health Protection, National Notifiable Diseases Surveillance System, Australian Government Department of Health and Ageing, 2011.
An Advisory Committee Statement. National Advisory Committee on Immunization. Statement on bacille Calmette-Guérin (BCG) Vaccine. Canada Commun Dis Rep 2004;30:ACS 5.
Altes HK, Dijkstra F, Lugnèr A, Cobelens F, Wallinga J. Targeted BCG vaccination against severe tuberculosis in low prevalence settings: epidemiologic and economic assessment. Epidemiology 2009;20(4):562–568.
Krause VL. Tuberculosis in the young: focusing on those at risk. Med J Aust 1998;168:100–101.
Beilby J, Reed J, Baker J, Wilson K, Sansbury M, Antic R, et al. Tuberculosis surveillance in the South Australian Aboriginal community. Med J Aust 1990;153:149–155.
Plant AJ, Krause VL, Condon JR, Kerr C. Aborigines and tuberculosis: why they are at risk. Aust J Public Health 1995;19:487–491
Barry C, Konstantinos A, et al. Tuberculosis notifications in Australia, 2007. Commun Dis Intell 2009;33(3):304–315.
Johnson PD, Carlin JB, Bennett CM, Phelan PD, Starr M, Hulls J, et al. Prevalence of tuberculosis infection in Melbourne secondary school students. Med J Aust 1998;168:106–110.
Alperstein G, Morgan KR, Fett MJ, Nossar V, Stewart GJ. Prevalence of tuberculosis infection among primary school-entry children in Sydney. Aust N Z J Public Health 1996;20:123–128.
Markey P, Barclay L, Krause V. NT Mantoux school screening 1991–2000. Northern Territory Disease Control Bulletin 2002;9:6–9.
Broomell K, Antic R, Stapledon R. A decade of tuberculosis control in SA. [Abstract]. Program and Abstracts. The 2nd National Tuberculosis Conference: Australia’s regional role in tuberculosis control. 1997 Nov 17–18:38. Sydney: The Public Health Association of Australia, 1997.
Guidance for national tuberculosis programmes on the management of tuberculosis in children. WHO/HTM/TB/2006.371. WHO/FCH/CAH/2006.7
Setia MS. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis 2006;6(3):162–170.
NNDSS Annual Report Writing Group. Australia’s notifiable disease status, 2008: annual report of the National Notifiable Diseases Surveillance System – Other bacterial infections. Commun Dis Intell 2010;34(3):214.
Lotte A, Wasz-Hockert O, Poisson N, Engbaek H, Landmann H, Quast U, et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 1988;63:47–59.
Lotte A, Wasz-Hockett O, Poisson N, Dumitrescu N, Verron M. Complications induced by BCG vaccination; retrospective study. Bull Int Union Tuberc 1980;55:58–67.
Turnbull FM, McIntyre PB, Achat HM, Wang H, Stapledon R, Gold M, et al. National study of adverse reactions after vaccination with Bacille Calmette-Guérin. Clin Infect Dis 2002;34:447–453.
Lugosi L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology. A review. Tuber Lung Dis 1992;73:252–261.
Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996;348:17–24.
Tala-Heikkila MM, Tuominen JE, Tala EO. Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence. Am J Respir Crit Care Med 1998;157:1324–1327.
Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005;366:1290–1295.
Global tuberculosis programme and global programme on vaccines: Statement on BCG revaccination for the prevention of tuberculosis. Wkly Epidemiol Rec 1995;70:229–231
Griffin JF, Chinn DN, Rodgers CR, Mackintosh CG. Optimal models to evaluate the protective efficacy of tuberculosis vaccines. Tuber (Edinb) 2001;81:133–139.
Orme IM. Progress in the development of new vaccines against tuberculosis. Int J Tuberc Lung Dis 1997;1:95–100.
Doherty TM, Andersen P. Vaccines for tuberculosis: novel concepts and recent progress. Clin Microbiol Rev 2005;18:687–702.
Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998;2:200–207.
Downloads
Published
How to Cite
License
Copyright (c) 2013 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
